Arix Bioscience

Sorriso Pharmaceuticals is a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of inflammatory disease, including Crohn’s disease and ulcerative colitis. The Sorriso platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the intestinal system. The company was founded in 2020 and is based in San Diego, California.

Depixus includes a Full genome analysis, which necessitates technologies capable of reading DNA, RNA, and their base changes. The dynamics of this cannot be captured with single-molecule precision by today's sequencing technology.

Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering, and developing innovative treatments for patients with severe hematologic disorders. The company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias and diamond-blackfan anemia.

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.The company leverages insights into gasdermin biology and innate immunity to develop medicines with lead compounds that target and inhibit the pore-forming protein that mediates the release of inflammatory cytokines, alarmins, DNA and NETs, enabling patients to get relief from inflammatory diseases.

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.

Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

VelosBio is an operator of a clinical-stage biopharmaceutical company intended to develop novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. The company's ROR1-directed therapeutics is a cell-surface protein that is expressed on many hematologic and solid tumors but is absent from normal tissues, making it an attractive tumor-specific therapeutic target and has demonstrated positive preclinical results in tumor models, enabling institutions to get novel targeted therapies for use as monotherapy or in combination across a broad range of cancers. It was founded in 2017 and headquartered in San Diego, California.

Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.The company leverages insights into gasdermin biology and innate immunity to develop medicines with lead compounds that target and inhibit the pore-forming protein that mediates the release of inflammatory cytokines, alarmins, DNA and NETs, enabling patients to get relief from inflammatory diseases.

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Atox Bio is a biotechnology company that specializes in infectious diseases, immunomodulators, and critical care.It focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well as ischemia/reperfusion injuries. The company was founded in 2003 and headquartered in HaMerkaz, Israel.

Autolus Therapeutics is working on next-generation programmed T cell treatments for the treatment of cancer. The company's pipeline includes Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Autolus was established in 2014 by Tim Funnell and Martin Pule in London, England.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology. The company focuses on heterogeneous genetic disorders that primarily manifest in bone dysfunction. In depth understanding of disease mechanism will allow PreciThera’s targeted strategies to meaningfully impact both the skeletal symptoms as well as the extraskeletal issues found in these patients.

LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases. It is committed to delivering genetic medicine to pediatric patients with rare diseases. Their proprietary technology based on the non-pathogenic adeno-associated viral vector offers superior efficiency and safety compared to all competitors on the market and is uniquely suited for the treatment of children as well as adults.

Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases. Mitochondria generates ATP, the energy source for all cellular activities. Mitochondria are also involved in other essential cellular functions, including calcium sequestration, amino acid and lipid metabolism, keeping balanced redox potential and orchestrating programmed cell death. In neurons in particular, mitochondria are very dynamic organelles that constantly undergo fission (division) and fusion. This process, called mitochondrial dynamics, is critical in maintaining healthy and functional mitochondria under both normal conditions and in response to stress and in ensuring having viable mitochondria along the axons and in the synaptic boutons. A defect in either fusion or fission limits mitochondrial motility, decreases energy production, increases oxidative stress and activates pro-apoptotic signaling thereby promoting cell dysfunction and death. Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives. It aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics.

Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

Autolus Therapeutics is working on next-generation programmed T cell treatments for the treatment of cancer. The company's pipeline includes Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Autolus was established in 2014 by Tim Funnell and Martin Pule in London, England.